Johnson & Johnson SWOT Analysis
Diversified healthcare giant with leading positions in pharmaceuticals (oncology, immunology) and medical devices across global markets.
PharmaceuticalsLast edited 2026-03-26T10:00:00Z
★ 重要ポイント
- 1最大の強み — Diversified Healthcare Portfolio: Broad presence across pharmaceuticals and medical devices provides revenue stability…
- 2最大の弱み — Litigation Exposure: Ongoing product liability lawsuits (talc, opioids) create financial uncertainty and reputational…
- 3最大の機会 — Oncology Pipeline Expansion: Multiple late-stage oncology and immunology assets could drive the next wave of blockbuster…
Johnson & Johnson SWOTスナップショット
| カテゴリ | 主な要因（上位3件） |
|---|---|
| 強み |
|
| 弱み |
|
| 機会 |
|
| 脅威 |
|
The SWOT
every quadrant, every point ↘Johnson & Johnsonの強み（2026年）
6Diversified Healthcare Portfolio: Broad presence across pharmaceuticals and medical devices provides revenue stability and cross-selling opportunities that pure-play competitors lack.
Strong Balance Sheet: One of the few AAA-rated corporations globally, with robust cash generation that funds R&D, dividends, and strategic acquisitions simultaneously.
Global Regulatory Expertise: Decades of navigating FDA, EMA, and global regulatory frameworks provide a competitive moat in drug approvals and medical device clearances.
Robust Pipeline: Strong clinical pipeline across oncology, immunology, and neuroscience with multiple late-stage assets poised for near-term commercial launches.
Trusted Brand: One of the most recognized healthcare brands worldwide, with long-standing relationships across hospitals, physicians, and payers.
Manufacturing Scale: Global manufacturing and supply chain operations provide cost advantages and reliability that smaller competitors cannot match.
Johnson & Johnsonの弱み（2026年）
6Litigation Exposure: Ongoing product liability lawsuits (talc, opioids) create financial uncertainty and reputational headwinds that weigh on valuation.
Mature Product Slowdown: Slower growth in mature product lines and patent expirations require continuous pipeline replenishment to maintain revenue growth.
Organizational Complexity: Large, complex organizational structure can slow decision-making and reduce agility compared to focused biotech competitors.
Blockbuster Dependence: Heavy reliance on key franchises like Stelara and Darzalex means patent cliffs create concentrated revenue risk.
US Pricing Pressure: Drug pricing reforms and payer pushback in the United States compress margins on pharmaceutical products.
Integration Challenges: Large-scale M&A and organizational restructuring create integration complexity and execution risk.
Johnson & Johnsonの機会（2026年）
6Oncology Pipeline Expansion: Multiple late-stage oncology and immunology assets could drive the next wave of blockbuster revenue growth.
Emerging Market Healthcare: Rising healthcare demand and expanding insurance coverage in emerging markets represent a massive growth opportunity.
Medtech Innovation: Digital surgery tools, robotic platforms, and connected devices can drive premium pricing and market share gains in medical devices.
Strategic M&A: Targeted acquisitions to fill pipeline gaps and enter new therapeutic areas, leveraging the strong balance sheet.
AI Clinical Development: Using AI and machine learning to accelerate clinical trials, reduce development costs, and improve success rates.
Value-Based Care: Partnering with payers and health systems on value-based contracting that demonstrates real-world outcomes and supports premium pricing.
Johnson & Johnsonの脅威（2026年）
6Ongoing Litigation Costs: Legal settlements and defense costs from talc, opioid, and other lawsuits could total billions and damage the brand.
Drug Pricing Reforms: Legislative pricing reforms in the US and reference pricing in other markets could meaningfully compress pharmaceutical margins.
Biosimilar Competition: Patent expirations on key biologics will face aggressive biosimilar competition, eroding revenue on established franchises.
Regulatory Scrutiny: Heightened FDA and global regulatory scrutiny on safety, manufacturing, and compliance can delay approvals and increase costs.
Currency Volatility: Significant international revenue exposure creates FX translation risk that can mask or amplify underlying business performance.
Supply Chain Disruptions: Geopolitical tensions and pandemic aftereffects continue to create supply chain vulnerabilities for critical healthcare products.
TOWS Strategy Matrix
PROFrom insight to action — pairing the four quadrants into concrete strategies.
SOGrowthStrengths × Opportunities
Global Oncology Launch: Leverage regulatory expertise and global distribution to rapidly scale oncology and immunology pipeline assets across major markets.
Medtech Digital Platform: Combine manufacturing scale with digital surgery and robotic innovation to create an integrated medtech platform that commands premium pricing.
WOTurnaroundWeaknesses × Opportunities
Portfolio Simplification: Streamline the organizational structure and divest non-core assets to improve focus, agility, and R&D efficiency across key therapeutic areas.
Litigation Risk Management: Strengthen proactive litigation management and product safety governance to reduce exposure and protect the trusted brand reputation.
STDefenseStrengths × Threats
IP and Lifecycle Defense: Aggressively defend intellectual property and execute lifecycle management strategies to extend blockbuster franchise revenue against biosimilar competition.
Supply Chain Resilience: Diversify manufacturing footprint and build strategic inventory buffers to protect against supply chain disruptions in critical healthcare products.
WTRetreatWeaknesses × Threats
High-Litigation Exit: Reduce exposure to product lines with disproportionate litigation risk, reallocating resources toward pipeline assets with cleaner risk profiles.
Cash Preservation: Maintain substantial cash reserves and conservative capital allocation to absorb legal settlements and weather pricing reform impacts.
make it yours ↘
Want to customize this analysis?
Tailor this Johnson & Johnson SWOT to your specific context — your market, your goals, your strategy.
SISTER SITE · FRAMEWORKLIST.COM
Beyond SWOT: other frameworks to try
SWOT is one of 100+ thinking frameworks on FrameworkList — covering strategy, prioritization, risk, business models, and decision-making.
Strategy
Porter's Five Forces
Map industry rivalry, suppliers, buyers, entrants, substitutes.
Strategy
PESTEL
Scan political, economic, social, technological, environmental, legal forces.
Risk
Pre-mortem
Imagine the failure first, then work backwards to prevent it.
Prioritization
RICE Scoring
Prioritize by reach × impact × confidence ÷ effort.
Business model
Lean Canvas
One-page model for problem, solution, channels, and key metrics.
Goals
OKR
Objectives + measurable Key Results to align teams on outcomes.
よくある質問
Johnson & JohnsonのSWOT分析における強みは何ですか？
- Diversified Healthcare Portfolio: Broad presence across pharmaceuticals and medical devices provides revenue stability and cross-selling opportunities that pure-play competitors lack.
- Strong Balance Sheet: One of the few AAA-rated corporations globally, with robust cash generation that funds R&D, dividends, and strategic acquisitions simultaneously.
- Global Regulatory Expertise: Decades of navigating FDA, EMA, and global regulatory frameworks provide a competitive moat in drug approvals and medical device clearances.
- Robust Pipeline: Strong clinical pipeline across oncology, immunology, and neuroscience with multiple late-stage assets poised for near-term commercial launches.
- Trusted Brand: One of the most recognized healthcare brands worldwide, with long-standing relationships across hospitals, physicians, and payers.
- Manufacturing Scale: Global manufacturing and supply chain operations provide cost advantages and reliability that smaller competitors cannot match.
Johnson & JohnsonのSWOT分析における弱みは何ですか？
- Litigation Exposure: Ongoing product liability lawsuits (talc, opioids) create financial uncertainty and reputational headwinds that weigh on valuation.
- Mature Product Slowdown: Slower growth in mature product lines and patent expirations require continuous pipeline replenishment to maintain revenue growth.
- Organizational Complexity: Large, complex organizational structure can slow decision-making and reduce agility compared to focused biotech competitors.
- Blockbuster Dependence: Heavy reliance on key franchises like Stelara and Darzalex means patent cliffs create concentrated revenue risk.
- US Pricing Pressure: Drug pricing reforms and payer pushback in the United States compress margins on pharmaceutical products.
- Integration Challenges: Large-scale M&A and organizational restructuring create integration complexity and execution risk.
Johnson & JohnsonのSWOT分析における機会は何ですか？
- Oncology Pipeline Expansion: Multiple late-stage oncology and immunology assets could drive the next wave of blockbuster revenue growth.
- Emerging Market Healthcare: Rising healthcare demand and expanding insurance coverage in emerging markets represent a massive growth opportunity.
- Medtech Innovation: Digital surgery tools, robotic platforms, and connected devices can drive premium pricing and market share gains in medical devices.
- Strategic M&A: Targeted acquisitions to fill pipeline gaps and enter new therapeutic areas, leveraging the strong balance sheet.
- AI Clinical Development: Using AI and machine learning to accelerate clinical trials, reduce development costs, and improve success rates.
- Value-Based Care: Partnering with payers and health systems on value-based contracting that demonstrates real-world outcomes and supports premium pricing.
Johnson & JohnsonのSWOT分析における脅威は何ですか？
- Ongoing Litigation Costs: Legal settlements and defense costs from talc, opioid, and other lawsuits could total billions and damage the brand.
- Drug Pricing Reforms: Legislative pricing reforms in the US and reference pricing in other markets could meaningfully compress pharmaceutical margins.
- Biosimilar Competition: Patent expirations on key biologics will face aggressive biosimilar competition, eroding revenue on established franchises.
- Regulatory Scrutiny: Heightened FDA and global regulatory scrutiny on safety, manufacturing, and compliance can delay approvals and increase costs.
- Currency Volatility: Significant international revenue exposure creates FX translation risk that can mask or amplify underlying business performance.
- Supply Chain Disruptions: Geopolitical tensions and pandemic aftereffects continue to create supply chain vulnerabilities for critical healthcare products.
More Examples
B
Blackstone
資産運用
世界最大のオルタナティブ資産運用会社。プライベートエクイティ、不動産、クレジット・保険、ヘッジファンドソリューションにわたり、機関投資家、そして次第に個人投資家に代わって投資する。Q1 2026にBlackstoneは記録的な1兆3040億ドルのAUM（+12%）を達成、フィー稼得AUMは9376億ドル（+9%）、パーマネント資本は5397億ドル（+16%）。分配可能利益は25%増の17.6億ドル（1.36ドル/株）、フィー関連利益は23%増の15.5億ドル。総流入は同四半期685億ドル（LTM 2463億ドル）で、クレジット・保険事業だけで370億ドルを取り込み、AUMを18%増の4575億ドルへ引き上げた。BREITは純流入プラスに回帰（12億ドル調達、+44%、純リターン9.3%、公開REIT指数を約60%上回る）。本SWOTは「ツースピード・テスト」を中心に据える — Blackstoneの速く耐久性のあるフィー・エンジン（何かを売ることに依存しない、パーマネント資本とクレジット上のフィー関連利益）が、遅く循環的な実現化エンジン（低調なM&A/IPOエグジット市場に制約されるキャリードインタレスト）が再加速するのを待つ間、総利益を成長させ続けられるほど速く複利成長できるか。Q2 2026は2026年7月23日に発表。
Read analysis →R(
RTX (Raytheon)
航空宇宙・防衛
世界最大級の航空宇宙・防衛企業（旧Raytheon Technologies）で、3つのフランチャイズ事業を運営する — Pratt & Whitney（ジェットエンジン、GTF）、Collins Aerospace（アビオニクス、機体構造、キャビンシステム）、Raytheon（ミサイル、防空・ミサイル防衛、レーダー）。FY2025純売上は約886億ドル（Pratt & Whitney 329.2億ドル+17.3%、Collins 302.0億ドル+6.8%、Raytheon 280.4億ドル+5.0%）。RTXは記録的な2710億ドルの受注残（+25%）を民間約1620億ドル／防衛約1090億ドルに分割して抱え、Q1 2026はビート＆レイズだった：調整後売上221億ドル（+9%）、調整後EPS 1.78ドル（+21%、コンセンサス1.52ドル）、FY2026ガイダンスを売上925～935億ドル、EPS 6.70～6.90ドル、フリーキャッシュフロー82.5～87.5億ドルへ引き上げ。本SWOTは「デュアルサイクル・テスト」を中心に据える — RTXが民間アフターマーケットのエンジン（Pratt アフターマーケット+19%）と防衛受注残のエンジン（Raytheon +9%オーガニック、マージン+150bp）を同時にフル稼働させられるか、PrattのGTF粉末金属マージン回復をスイング要因として、関税とBoeing/Airbusの生産レートリスクを吸収しつつ。Q2 2026は2026年7月23日に発表。
Read analysis →BO
Blue Origin
航空宇宙・宇宙
ジェフ・ベゾスの宇宙企業。2026年7月に1,300億ドルの評価額で100億ドルを調達 — 約26年の自己資金運営を経て初の外部資金調達ラウンドで、Coatueが約40億ドル、ベゾスが約20億ドルをコミットした。Blue OriginはNew Glennが軌道到達とブースター回収を実証済みで、34億ドルのNASA Blue Moon月着陸船契約とAmazon Kuiperの最大27回の打ち上げを保有し、5,408基のTeraWaveコンステレーションとProject Sunrise宇宙データセンターに大きく賭けている。しかしNew Glennの飛行はわずか3回にとどまり、2026年4月の飛行では顧客の衛星を軌道に取り残し、2026年5月28日にはスタティックファイア試験でブースターNG-4と唯一の軌道打ち上げ台LC-36を破壊した。本SWOTは「スケール前の信頼性テスト」を中心に据える — Blue Originが、いまだ定常的に飛べていないロケットに依存するスケールへの賭け（TeraWave、Project Sunrise、Kuiper、Artemis）を正当化するに足る速さで、New Glennの打ち上げ頻度と信頼性を回復し、規模で約13倍のライバルSpaceXに対抗しつつ1,300億ドルの評価額を裏付けられるか、である。
Read analysis →★ AI AGENT
Analyze any company in 30 seconds
47,000+ analyses created on SWOTPal — yours is next.
Analyze Free →